Summary
The difference in the hearing threshold before and after treatment with cis-diaminnedichloroplatinum (DDP) is analysed in 69 patients. Hearing loss due to DDP treatment is mainly limited to 8,000 Hz and the incidence is about 40%. The effect of DDP is dose-related, although even at the lowest dose 20% of the patients are affected. The age of the patients is not an important factor. Loss of hearing due to DDP treatment occurs independent of any pre-existent hearing loss although those patients with great pre-existent hearing loss do not show a further loss. Of the patients with hearing loss, 39% show a difference of 20 dB or more between the left and the right ear. Hearing loss due to DDP is of minor importance compared with many of the other side-effects of DDP.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Atherley GRE, Dingwall-Fordyce J (1963) The reliability of repeated auditory threshold determination. Br J Industr Med 20: 231–235
Aquilar-Markulis NV, Beckley S, Prior R, Mettlin C (1981) Auditory toxicity effects of long-term Cis-Dichlorodiammine-Platinum (II) therapy in genitourinary cancer patients J Surg Oncol 16: 111–123
Dreschler WA, Plomp R (1980) Relation between psychophysical data and speech perception for hearing impaired subjects (I). J Acoust Soc Am 68: 1608–1615
Festen JF, Plomp R (1981) Relations between auditory functions in normal hearing. J Acoust Soc Am 70: 356–369
Hayes DM, Cvitkovic E, Colbey RB, Schreiner E, Helson L, Krakoff JH (1977) High dose cis-platinum diammine dichloride. Cancer 39: 1372–1381
Helson L, Okonkwo E, Anton L, Cvitkovic E (1978) Cis-Platinum ototoxicity. Clin Toxicol 13: 469–478
Lippman AJ, Helson C, Helson L, Krakoff JH (1973) Clinical trials of cis-diamminedi-chloroplatinum (NSC-119875). Cancer Chemother Rep 57: 191–200
Piel JJ, Meijer D, Perlia CP, Wolfe VJ (1974) Effects of cis-diamminedichloroplatinum (NSC-119875) on hearing function in man. Cancer Chemother Rep 54: 871–875
Reddel RR, Kefford RF, Grant JM, Coates AS, Fox RM, Tattersall MHN (1982) Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep 66: 19–23
Rosenberg (1977) Noble metal complexes in cancer chemotherapy. Adv Experiment Med Biol 91: 129–150
Vermorken JB, Kapteyn TS, Hart AAM, Pinedo HM (1983) Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration. Eur J Cancer Clin Oncol 19: 53–58
Witting EG, Hughson W (1940) Inherent accuracy of a series of repeated clinical audiograms. Laryngoscope 50: 259–269
Author information
Authors and Affiliations
Additional information
Supported by the Heinsius Houbolt Foundation
Rights and permissions
About this article
Cite this article
van Zeijl, L.G.P.M., Conijn, E.A.J.G., Rodenburg, M. et al. Analysis of hearing loss due to cis-diamminedichloroplatinum-II. Arch Otorhinolaryngol 239, 255–262 (1984). https://doi.org/10.1007/BF00464252
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00464252